chloroquine has been researched along with Torsade de Pointes in 11 studies
Chloroquine: The prototypical antimalarial agent with a mechanism that is not well understood. It has also been used to treat rheumatoid arthritis, systemic lupus erythematosus, and in the systemic therapy of amebic liver abscesses.
chloroquine : An aminoquinoline that is quinoline which is substituted at position 4 by a [5-(diethylamino)pentan-2-yl]amino group at at position 7 by chlorine. It is used for the treatment of malaria, hepatic amoebiasis, lupus erythematosus, light-sensitive skin eruptions, and rheumatoid arthritis.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To analyze the cases of torsade de pointes (TdP) and related symptoms reported in association with chloroquine (CQ), hydroxychloroquine (HCQ), and azithromycin (AZT) to the World Health Organization (WHO) global database of individual case safety reports (ICSRs) for drug monitoring (VigiBase) using qualitative and quantitative pharmacovigilance approaches." | 8.02 | Torsade de pointes associated with chloroquine, hydroxychloroquine, and azithromycin: a retrospective analysis of individual case safety reports from VigiBase. ( Saint-Gerons, DM; Tabarés-Seisdedos, R, 2021) |
| "To analyze the cases of torsade de pointes (TdP) and related symptoms reported in association with chloroquine (CQ), hydroxychloroquine (HCQ), and azithromycin (AZT) to the World Health Organization (WHO) global database of individual case safety reports (ICSRs) for drug monitoring (VigiBase) using qualitative and quantitative pharmacovigilance approaches." | 4.02 | Torsade de pointes associated with chloroquine, hydroxychloroquine, and azithromycin: a retrospective analysis of individual case safety reports from VigiBase. ( Saint-Gerons, DM; Tabarés-Seisdedos, R, 2021) |
| " However, some of these medications have potential cardiac adverse effects." | 2.66 | Cardiac safety of off-label COVID-19 drug therapy: a review and proposed monitoring protocol. ( Lazar, S; Naksuk, N; Peeraphatdit, TB, 2020) |
| " Food and Drug Administration's Adverse Event Reporting System (FAERS) (>13 million total reports) were used." | 1.62 | Safety signals for QT prolongation or Torsades de Pointes associated with azithromycin with or without chloroquine or hydroxychloroquine. ( Brown, JD; Cicali, B; Henriksen, CH; Sarayani, A, 2021) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (9.09) | 29.6817 |
| 2010's | 1 (9.09) | 24.3611 |
| 2020's | 9 (81.82) | 2.80 |
| Authors | Studies |
|---|---|
| Chotsiri, P | 1 |
| Tarning, J | 1 |
| Hoglund, RM | 1 |
| Watson, JA | 1 |
| White, NJ | 1 |
| Bauman, JL | 1 |
| Tisdale, JE | 1 |
| Sarayani, A | 1 |
| Cicali, B | 1 |
| Henriksen, CH | 1 |
| Brown, JD | 1 |
| Funck-Brentano, C | 1 |
| Salem, JE | 1 |
| Nguyen, LS | 1 |
| Drici, MD | 1 |
| Roden, DM | 1 |
| Naksuk, N | 1 |
| Lazar, S | 1 |
| Peeraphatdit, TB | 1 |
| Szekely, Y | 1 |
| Lichter, Y | 1 |
| Shrkihe, BA | 1 |
| Bruck, H | 1 |
| Oster, HS | 1 |
| Viskin, S | 1 |
| Alkasir, A | 1 |
| Lippmann, S | 1 |
| Ehrlich, H | 1 |
| Elkbuli, A | 1 |
| Saint-Gerons, DM | 1 |
| Tabarés-Seisdedos, R | 1 |
| Yelve, K | 1 |
| Phatak, S | 1 |
| Patil, MA | 1 |
| Pazare, AR | 1 |
| Mansfield, RJ | 1 |
| Thomas, RD | 1 |
1 review available for chloroquine and Torsade de Pointes
| Article | Year |
|---|---|
Cardiac safety of off-label COVID-19 drug therapy: a review and proposed monitoring protocol.
Topics: Anti-Bacterial Agents; Antibodies, Monoclonal; Antimalarials; Arrhythmias, Cardiac; Betacoronavirus; | 2020 |
10 other studies available for chloroquine and Torsade de Pointes
| Article | Year |
|---|---|
Pharmacometric and Electrocardiographic Evaluation of Chloroquine and Azithromycin in Healthy Volunteers.
Topics: Adult; Antimalarials; Azithromycin; Chloroquine; Coronavirus Infections; COVID-19 Drug Treatment; DN | 2022 |
Chloroquine and Hydroxychloroquine in the Era of SARS - CoV2: Caution on Their Cardiac Toxicity.
Topics: Cardiotoxicity; Chloroquine; COVID-19 Drug Treatment; Humans; Hydroxychloroquine; Risk Factors; SARS | 2020 |
Safety signals for QT prolongation or Torsades de Pointes associated with azithromycin with or without chloroquine or hydroxychloroquine.
Topics: Antiviral Agents; Azithromycin; Chloroquine; COVID-19; COVID-19 Drug Treatment; Drug Interactions; D | 2021 |
Response to the editorial "COVID-19 in patients with cardiovascular diseases": Covid-19 treatment with hydroxychloroquine or chloroquine and azithromycin: A potential risk of Torsades de Pointes.
Topics: Azithromycin; Betacoronavirus; Cardiovascular Diseases; Chloroquine; Coronavirus Infections; COVID-1 | 2020 |
Chloroquine-induced torsades de pointes in a patient with coronavirus disease 2019.
Topics: Aged, 80 and over; Antimalarials; Betacoronavirus; Chloroquine; Coronavirus Infections; COVID-19; CO | 2020 |
COVID-19 and Cardiac Concerns for Psychiatric Patients.
Topics: Antidepressive Agents; Antiviral Agents; Arrhythmias, Cardiac; Atrial Fibrillation; Atrioventricular | 2020 |
Cardiac arrhythmias in COVID-19 patients: A combination of viral comorbidities and pro-arrhythmic drug interactions.
Topics: Angiotensin-Converting Enzyme 2; Anti-Bacterial Agents; Antimalarials; Arrhythmias, Cardiac; Azithro | 2021 |
Torsade de pointes associated with chloroquine, hydroxychloroquine, and azithromycin: a retrospective analysis of individual case safety reports from VigiBase.
Topics: Adult; Aged; Azithromycin; Chloroquine; Drug Therapy, Combination; Female; Humans; Hydroxychloroquin | 2021 |
Syncope in a patient being treated for hepatic and intestinal amoebiasis.
Topics: Amebicides; Antiprotozoal Agents; Chloroquine; Dysentery, Amebic; Furans; Humans; Hypokalemia; Liver | 2012 |
Recurrent syncope. Drug induced long QT syndrome.
Topics: Adult; Anti-Allergic Agents; Antimalarials; Astemizole; Chloroquine; Electrocardiography; Humans; Lo | 2001 |